WBP2 and breast carcinoma: Consistently, miR-23a inhibitor upregulated endogenous WBP2 protein (Fig. 6a, i) and mRNA (Fig. 6a, ii) expression, supporting the notion that miR-23a controls the basal state of WBP2 in breast cancer cells.